Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,441 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.
Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K. Furst DE, et al. Among authors: emery p. Ann Rheum Dis. 2011 Mar;70 Suppl 1:i2-36. doi: 10.1136/ard.2010.146852. Ann Rheum Dis. 2011. PMID: 21339216 No abstract available.
Issues in rheumatoid arthritis.
Emery P, Smolen J. Emery P, et al. Lancet. 1999 Apr 3;353(9159):1186. doi: 10.1016/S0140-6736(05)74407-X. Lancet. 1999. PMID: 10210007 No abstract available.
Access to disease modifying treatments for rheumatoid arthritis patients.
Furst DE, Breedveld FC, Burmester GR, Crofford L, Emery P, Feldman M, Kalden JR, Kavanaugh A, Keystone E, Lipsky PE, Maini RN, Moreland L, Smolen JS, Van De Putte L, Vischer T, Weinblatt M, Weissman M. Furst DE, et al. Among authors: emery p. Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I129-30. doi: 10.1136/ard.58.2008.i129. Ann Rheum Dis. 1999. PMID: 10577989 Free PMC article. Review. No abstract available.
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Maini R, et al. Among authors: emery p. Lancet. 1999 Dec 4;354(9194):1932-9. doi: 10.1016/s0140-6736(99)05246-0. Lancet. 1999. PMID: 10622295 Clinical Trial.
Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis.
Smolen JS, Breedveld FC, Burmester GR, Combe B, Emery P, Kalden JR, Klareskog L, Maini RN, Numo R, van De Putte LB, van Riel PL, Rodriguez-Valverde V. Smolen JS, et al. Among authors: emery p. Ann Rheum Dis. 2000 Jul;59(7):504-5. doi: 10.1136/ard.59.7.504. Ann Rheum Dis. 2000. PMID: 10873957 Free PMC article. Review. No abstract available.
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000).
Furst DE, Breedveld FC, Burmester GR, Crofford JJ, Emery P, Feldmann M, Kalden JR, Kavanaugh AF, Keystone EC, Klareskog LG, Lipsky PE, Maini RN, Russell AS, Scott DL, Smolen JS, Van de Putte LB, Visher TL, Weisman MH. Furst DE, et al. Among authors: emery p. Ann Rheum Dis. 2000 Nov;59 Suppl 1(Suppl 1):i1-2. doi: 10.1136/ard.59.suppl_1.i1. Ann Rheum Dis. 2000. PMID: 11053077 Free PMC article. Review. No abstract available.
1,441 results